Anti-coagulant Activity of a Metalloprotease: Further Characterization from the Indian Cobra (Naja Naja) Venom

Overview

Journal J Thromb Thrombolysis

Specialty Cardiology & Vascular Diseases

Date 2009 Jul 25

PMID 19629641

Citations 11

Authors

M S Kumar

V R Devaraj

B S Vishwanath

K Kemparaju

Affiliations

Soon will be listed here.

Abstract

A high molecular mass, non toxic metalloprotease the NN-PF3 with the bound Ca(2+) and Zn(2+) from the Naja naja venom has been studied further for its anticoagulant property. The molecular mass by MALDI-TOF mass spectrometry was 67.81 kDa. The NN-PF3 exhibited fibrin(ogen)olytic activity. In addition to fibrinogen, NN-PF3 hydrolyzed blood and plasma clot with the later hydrolyzed about one fold higher. The alpha polymer of fibrin was preferentially hydrolyzed over the alpha chain but the beta chain and gamma-gamma dimer remained untouched. It was devoid of plasminogen activation property. It prolonged the activated partial thromboplastin time, prothrombin time and the thrombin clotting time of citrated human plasma. It did not affect the thrombin activity. In mice, defibrinogentaion, prolonged bleeding time (P < 0.01) and reduced fibrinogen level were observed following intravenous injection. Human plasma or alpha2-macroglobulin did not, but the polyvalent anti-venom inhibited the NN-PF3 activity. In contrast to most snake venom metalloproteases, it did not degrade extra cellular matrix proteins.

Citing Articles

A comparative cross-reactivity and paraspecific neutralization study on Hypnale hypnale, Echis carinatus, and Daboia russelii monovalent and therapeutic polyvalent anti-venoms.

Sandesha V, Darshan B, Tejas C, Girish K, Kempaiah K PLoS Negl Trop Dis. 2022; 16(3):e0010292.

PMID: 35344557 PMC: 9037957. DOI: 10.1371/journal.pntd.0010292.

Venomics of the Enigmatic Andaman Cobra () and the Preclinical Failure of Indian Antivenoms in Andaman and Nicobar Islands.

Attarde S, Khochare S, Iyer A, Dam P, Martin G, Sunagar K Front Pharmacol. 2021; 12:768210.

PMID: 34759827 PMC: 8573199. DOI: 10.3389/fphar.2021.768210.

State-of-the-art review - A review on snake venom-derived antithrombotics: Potential therapeutics for COVID-19-associated thrombosis?.

Kalita B, Saviola A, Samuel S, Mukherjee A Int J Biol Macromol. 2021; 192:1040-1057.

PMID: 34656540 PMC: 8514616. DOI: 10.1016/j.ijbiomac.2021.10.015.

Evaluation of the merit of the methanolic extract of to supplement anti-snake venom in reversing secondary hemostatic abnormalities induced venom.

Nayak A, Kumar N, Shenoy S, Roche M 3 Biotech. 2021; 11(5):228.

PMID: 33959471 PMC: 8060375. DOI: 10.1007/s13205-021-02766-z.

A Wolf in Another Wolf's Clothing: Post-Genomic Regulation Dictates Venom Profiles of Medically-Important Cryptic Kraits in India.

Sunagar K, Khochare S, Senji Laxme R, Attarde S, Dam P, Suranse V Toxins (Basel). 2021; 13(1).

PMID: 33477742 PMC: 7832344. DOI: 10.3390/toxins13010069.

References

Koh D, Armugam A, Jeyaseelan K . Snake venom components and their applications in biomedicine. Cell Mol Life Sci. 2006; 63(24):3030-41. PMC: 11135979. DOI: 10.1007/s00018-006-6315-0. View

Matsui T, Fujimura Y, Titani K . Snake venom proteases affecting hemostasis and thrombosis. Biochim Biophys Acta. 2000; 1477(1-2):146-56. DOI: 10.1016/s0167-4838(99)00268-x. View

Daoud E, Tu A, el-Asmar M . Mechanism of the anticoagulant, Cerastase F-4, isolated from Cerastes cerastes (Egyptian sand viper) venom. Thromb Res. 1986; 41(6):791-9. DOI: 10.1016/0049-3848(86)90377-4. View

Markland Jr F . Snake venom fibrinogenolytic and fibrinolytic enzymes: an updated inventory. Registry of Exogenous Hemostatic Factors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1998; 79(3):668-74. View

Evans H . Cleavage of the A alpha-chain of fibrinogen and the alpha-polymer of fibrin by the venom of spitting cobra (Naja nigricollis). Biochim Biophys Acta. 1981; 660(2):219-26. DOI: 10.1016/0005-2744(81)90163-7. View

Kisiel W, Kondo S, Smith K, McMullen B, SMITH L . Characterization of a protein C activator from Agkistrodon contortrix contortrix venom. J Biol Chem. 1987; 262(26):12607-13. View

Zhang Y, Wisner A, Xiong Y, Bon C . A novel plasminogen activator from snake venom. Purification, characterization, and molecular cloning. J Biol Chem. 1995; 270(17):10246-55. DOI: 10.1074/jbc.270.17.10246. View

Estevao-Costa M, DINIZ C, Magalhaes A, Markland F, Sanchez E . Action of metalloproteinases mutalysin I and II on several components of the hemostatic and fibrinolytic systems. Thromb Res. 2000; 99(4):363-76. DOI: 10.1016/s0049-3848(00)00259-0. View

Zingali R, Ferreira M, Assafim M, Frattani F, Monteiro R . Bothrojaracin, a Bothrops jararaca snake venom-derived (pro)thrombin inhibitor, as an anti-thrombotic molecule. Pathophysiol Haemost Thromb. 2006; 34(4-5):160-3. DOI: 10.1159/000092416. View

10.

Jagadeesha D, Shashidhara murthy R, Girish K, Kemparaju K . A non-toxic anticoagulant metalloprotease: purification and characterization from Indian cobra (Naja naja naja) venom. Toxicon. 2002; 40(6):667-75. DOI: 10.1016/s0041-0101(01)00216-1. View

11.

Zhu Z, Wu S . Fibrinogenolytic properties of natrahagin (a proteinase from cobra venom) and its effect on human platelet aggregation. Zhongguo Yao Li Xue Bao. 2001; 20(10):944-7. View

12.

Fox J, Serrano S . Structural considerations of the snake venom metalloproteinases, key members of the M12 reprolysin family of metalloproteinases. Toxicon. 2005; 45(8):969-85. DOI: 10.1016/j.toxicon.2005.02.012. View

13.

Moura-da-Silva A, Ramos O, Baldo C, Niland S, Hansen U, Ventura J . Collagen binding is a key factor for the hemorrhagic activity of snake venom metalloproteinases. Biochimie. 2007; 90(3):484-92. DOI: 10.1016/j.biochi.2007.11.009. View

14.

Kini R, Evans H . Inhibition of platelet aggregation by a fibrinogenase from Naja nigricollis venom is independent of fibrinogen degradation. Biochim Biophys Acta. 1991; 1095(2):117-21. DOI: 10.1016/0167-4889(91)90073-7. View

15.

Guo X, Zeng L, Lee W, Zhang Y, Jin Y . Isolation and cloning of a metalloproteinase from king cobra snake venom. Toxicon. 2007; 49(7):954-65. DOI: 10.1016/j.toxicon.2007.01.003. View

16.

Rajesh R, Gowda C, Nataraju A, Dhananjaya B, Kemparaju K, Vishwanath B . Procoagulant activity of Calotropis gigantea latex associated with fibrin(ogen)olytic activity. Toxicon. 2005; 46(1):84-92. DOI: 10.1016/j.toxicon.2005.03.012. View

17.

REID H, Chan K . The paradox in therapeutic defibrination. Lancet. 1968; 1(7541):485-6. DOI: 10.1016/s0140-6736(68)91463-3. View

18.

Bernardes C, Santos-Filho N, Costa T, Gomes M, Torres F, Costa J . Isolation and structural characterization of a new fibrin(ogen)olytic metalloproteinase from Bothrops moojeni snake venom. Toxicon. 2008; 51(4):574-84. DOI: 10.1016/j.toxicon.2007.11.017. View

19.

Loria G, Rucavado A, Kamiguti A, Theakston R, Fox J, Alape A . Characterization of 'basparin A,' a prothrombin-activating metalloproteinase, from the venom of the snake Bothrops asper that inhibits platelet aggregation and induces defibrination and thrombosis. Arch Biochem Biophys. 2003; 418(1):13-24. DOI: 10.1016/s0003-9861(03)00385-0. View

20.

Gene J, Roy A, Rojas G, Gutierrez J, Cerdas L . Comparative study on coagulant, defibrinating, fibrinolytic and fibrinogenolytic activities of Costa Rican crotaline snake venoms and their neutralization by a polyvalent antivenom. Toxicon. 1989; 27(8):841-8. DOI: 10.1016/0041-0101(89)90096-2. View